Digital Jagran

Information, Information and Information

Biotech

Big Pharma’s $7B Bet Signals Peak in In Vivo CAR-T Deal Rush

Eli Lilly’s $7B Kelonia deal highlights rising competition in CAR-T therapies, as Big Pharma races to acquire limited biotech targets.

Surya Pratap Singh

4/27/2026, 5:50:41 AM

0 min read

Big Pharma’s $7B Bet Signals Peak in In Vivo CAR-T Deal Rush | Digital Jagran | Digital Jagran